Endocrinology Drugs Market Share, Growth, Opportunities 2031
Endocrinology Drugs Market Share, Growth, Opportunities 2031
Segments - Endocrinology Drugs Market by Products (Hormone, Diabetes, Hypothyroidism, Hypogonadism, and Acromegaly) and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031
Upcoming
| Report ID :HC-2551
| 4.8 Rating
| 85 Reviews
| 188 Pages
| Format :
Report Description
Endocrinology Drugs Market Outlook 2031
The Global Endocrinology drugs market size was valued at USD 36.55 Billion in 2022 and is likely reach to USD 69.49 Billion by 2031, expanding at a CAGR of 7.4% during the forecast period, 2023–2031. The growth of the market is attributed to growing prevalence of endocrine diseases.
Growing geriatric population which is more vulnerable to suffer from such diseases owing to hormonal variations is estimated to fuel the market. Endocrinology drugs are used to treat complexities of the endocrine system and modulate the hormonal changes in the body.
They are specifically focused towards pituitary, endocrine organs, adrenals, thyroid, testes, ovaries, and pancreas that regulate hormone secretions.
Unhealthy lifestyle such as work stress, huge intake of cholesterol, and weight gain, eventually leads to inception of new drug delivery systems, malfunctioning of the system, and increasing disposable income which is expected to propel the market.
The adoption rate of formulations of existing drugs and novel dosage forms is expected to increase as the number of patients for the treatment of such disorders.
Market Trends, Drivers, Restraints, and Opportunities
- Rising prevalence of endocrine diseases are expected to drive endocrinology drugs market
- Rising geriatric population which is more vulnerable to suffer from such diseases, which is expected to boost the market.
- Unhealthy lifestyle such as work stress, high intake of cholesterol, and weight gain is expected to be a key factor to accelerate the market.
- Extensive research & development activities, inception of new drug delivery systems, and rising disposable income are expected to propel the market.
- Increasing adoption of formulations of existing drugs and novel dosage forms are the key drivers of the market in the coming years.
- Illegal use of drugs for better performance by sports professionals is expected to restrain the market growth.
Scope of Endocrinology Drugs Market Report
The report on the global endocrinology drugs market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Endocrinology Drugs Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2022 |
|
Historic Data |
2016–2021 |
|
Forecast Period |
2023–2031 |
|
Segmentation |
Products (Hormone, Diabetes, Hypothyroidism, Hypogonadism, and Acromegaly) |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
F. Hoffmann-La Roche AG.; Alacer Corporation; Pfizer Inc.; Abbott Laboratories; Novartis International AG; Eli Lilly and Company; Facet Biotech Corporation; Novo Nordisk A/S, and Sanofi. |
Endocrinology Drugs Market Segment Insights
The diabetes segment is expected to grow at a rapid pace
Based on products, the global endocrinology drugs market is segregated into hormone, diabetes, hypothyroidism, hypogonadism, and acromegaly. The diabetes segment accounts for a key share of the market owing to the presence of strong product pipelines and novel drug therapies.
Meanwhile, the hypogonadism segment is anticipated to expand at a rapid pace during the forecast period due to increasing prevalence of deficiency of testosterone and associated complications.
Endocrinology Drugs Market Regional Outlook
North America is anticipated to constitute a key market share
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America accounts for a key share of the market owing to rising prevalence of endocrine diseases and increasing adoption of hormone replacement therapies.
The market of Asia Pacific is estimated to expand at a rapid pace during the forecast period due to increasing R&D activities and growing healthcare infrastructure.
Segments
Products
- Hormone
- Diabetes
- Hypothyroidism
- Hypogonadism
- Acromegaly
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- F. Hoffmann-La Roche AG.
- Alacer Corporation
- Pfizer Inc.
- Abbott Laboratories
- Novartis International AG
- Eli Lilly and Company
- Facet Biotech Corporation
- Novo Nordisk A/S
- Sanofi
Competitive Landscape
Key players competing in the endocrinology drugs market include F. Hoffmann-La Roche AG.; Alacer Corporation; Pfizer Inc.; Abbott Laboratories; Novartis International AG; Eli Lilly and Company; Facet Biotech Corporation; Novo Nordisk A/S, and Sanofi.
Some of these players are using several market strategies such as acquisitions, merger, collaborations, partnerships, capacity expansion, and product launches to enhance their market shares and to generate revenue and raise their production line of the business in the coming years.
Table Of Content
1. Executive Summary2. Assumptions and Acronyms Used
3. Research Methodology
4. Endocrinology Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Endocrinology Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Endocrinology Drugs Market - Supply Chain
4.5. Global Endocrinology Drugs Market Forecast
4.5.1. Endocrinology Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Endocrinology Drugs Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Endocrinology Drugs Market Absolute $ Opportunity
5. Global Endocrinology Drugs Market Analysis and Forecast by Region
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Region
5.2.2. Y-o-Y Growth Projections by Region
5.3. Endocrinology Drugs Market Size and Volume Forecast by Region
5.3.1. North America
5.3.2. Latin America
5.3.3. Europe
5.3.4. Asia Pacific
5.3.5. Middle East and Africa (MEA)
5.4. Absolute $ Opportunity Assessment by Region
5.5. Market Attractiveness/Growth Potential Analysis by Region
5.6. Global Endocrinology Drugs Demand Share Forecast, 2019-2026
6. North America Endocrinology Drugs Market Analysis and Forecast
6.1. Introduction
6.1.1. Basis Point Share (BPS) Analysis by Country
6.1.2. Y-o-Y Growth Projections by Country
6.2. North America Endocrinology Drugs Market Size and Volume Forecast by Country
6.2.1. U.S.
6.2.2. Canada
6.3. Absolute $ Opportunity Assessment by Country
6.4. Market Attractiveness/Growth Potential Analysis
6.4.1. By Country
6.4.2. By Product Type
6.4.3. By Application
6.5. North America Endocrinology Drugs Demand Share Forecast, 2019-2026
7. Latin America Endocrinology Drugs Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.1.3. Latin America Average Pricing Analysis
7.2. Latin America Endocrinology Drugs Market Size and Volume Forecast by Country
7.2.1. Brazil
7.2.2. Mexico
7.2.3. Rest of Latin America
7.3. Absolute $ Opportunity Assessment by Country
7.4. Market Attractiveness/Growth Potential Analysis
7.4.1. By Country
7.4.2. By Product Type
7.4.3. By Application
7.5. Latin America Endocrinology Drugs Demand Share Forecast, 2019-2026
8. Europe Endocrinology Drugs Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Europe Average Pricing Analysis
8.2. Europe Endocrinology Drugs Market Size and Volume Forecast by Country
8.2.1. Germany
8.2.2. France
8.2.3. Italy
8.2.4. U.K.
8.2.5. Spain
8.2.6. Russia
8.2.7. Rest of Europe
8.3. Absolute $ Opportunity Assessment by Country
8.4. Market Attractiveness/Growth Potential Analysis
8.4.1. By Country
8.4.2. By Product Type
8.4.3. By Application
8.5. Europe Endocrinology Drugs Demand Share Forecast, 2019-2026
9. Asia Pacific Endocrinology Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Asia Pacific Average Pricing Analysis
9.2. Asia Pacific Endocrinology Drugs Market Size and Volume Forecast by Country
9.2.1. China
9.2.2. Japan
9.2.3. South Korea
9.2.4. India
9.2.5. Australia
9.2.6. Rest of Asia Pacific (APAC)
9.3. Absolute $ Opportunity Assessment by Country
9.4. Market Attractiveness/Growth Potential Analysis
9.4.1. By Country
9.4.2. By Product Type
9.4.3. By Application
9.5. Asia Pacific Endocrinology Drugs Demand Share Forecast, 2019-2026
10. Middle East & Africa Endocrinology Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Middle East & Africa Average Pricing Analysis
10.2. Middle East & Africa Endocrinology Drugs Market Size and Volume Forecast by Country
10.2.1. Saudi Arabia
10.2.2. South Africa
10.2.3. UAE
10.2.4. Rest of Middle East & Africa (MEA)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Market Attractiveness/Growth Potential Analysis
10.4.1. By Country
10.4.2. By Product Type
10.4.3. By Application
10.5. Middle East & Africa Endocrinology Drugs Demand Share Forecast, 2019-2026
11. Competition Landscape
11.1. Global Endocrinology Drugs Market: Market Share Analysis
11.2. Endocrinology Drugs Distributors and Customers
11.3. Endocrinology Drugs Market: Competitive Dashboard
11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
11.4.1. F. Hoffmann-La Roche AG.
11.4.2. Alacer Corporation
11.4.3. Pfizer Inc.
11.4.4. Abbott Laboratories
11.4.5. Novartis International AG
11.4.6. Eli Lilly and Company
11.4.7. Facet Biotech Corporation
Methodology
Related Reports
Some other reports from this category!
Our Clients
